Arkolith/Insider Trading/SABS/Form 4

Sessa Capital GP, LLC

DirectorSAB Biotherapeutics, Inc. (SABS) · full profile →Form 4 · filed Nov 14, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
5
0 non-derivative · 5 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 13, 2023Option exercise(M)13K——0
Nov 13, 2023Grant(A)13K$1000.00$13.3M31K
Nov 10, 2023Grant(A)13K——13K
Nov 10, 2023Grant(A)9K——21K
Nov 10, 2023Grant(A)22K——52K

Transaction Codes

M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001062993-23-020791) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML